hrp0094p2-258 | Growth hormone and IGFs | ESPE2021

Incidence of ALS deficiency in patients with growth hormone deficiency at tertiary pediatric endocrinology center

Rankova Kamelia , Iotova Violeta , Bocheva Yana , Shefket Sevim , Yordanova Nikolinka , Bazdarska Yuliya , Tsochev Kaloyan , Galcheva Sonya , Boyadzhiev Veselin ,

Acid-labile subunit (ALS) is a glycoprotein, which is produced in the liver in response to growth hormone (GH). The main role of ALS is to form a complex with insulin-like growth factor I (IGF-I) and IGF binding protein-3 (IGFBP-3) in order to extend their circulating half-life and thus support the action of GH. Although the mechanism and the consequences of ALS deficiency are well studied, ALS-deficient patients are still of research interest because of the unclear incidence ...

hrp0094p2-259 | Growth hormone and IGFs | ESPE2021

Presentation of IGF-1/IGFBP-3 molar ratio as an effective monitoring index during treatment of growth hormone deficient patients

Rankova Kamelia , Iotova Violeta , Bocheva Yana , Shefket Sevim , Boyadzhiev Veselin , Yordanova Nikolinka , Bazdarska Yuliya , Tsochev Kaloyan , Galcheva Sonya ,

Serum levels of insulin-like growth factor-1(IGF-1) are used universally for monitoring growth hormone (GH) therapy in patients with GH deficiency (GHD). However, the serum levels of IGF-1 are variable, therefore in the last years the serum levels of IGF binding protein-3 (IGFBP-3) and the molar ratio IGF-1/IGFBP-3 were introduced as more effective and stable parameters evaluating the safety and efficacy of GH treatment. Many studies present reference values of IGF-1, IGFBP-3 ...